Volume 04 Issue 10-2024
1
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
Malaria, caused by Plasmodium species, poses significant health challenges worldwide, particularly in endemic
regions. This study investigates the alterations in liver enzyme levels associated with Plasmodium vivax and
Plasmodium falciparum infections. We conducted a comparative analysis of liver function tests (LFTs) among
confirmed malaria patients infected with either species, alongside a control group of healthy individuals. Enzyme
levels, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and
bilirubin, were measured and analyzed. Our findings reveal a significant elevation in liver enzyme levels in patients
infected with both P. vivax and P. falciparum compared to controls, with P. falciparum infections showing more
pronounced derangements. The alterations in enzyme levels correlate with clinical severity and indicate potential
hepatic involvement in malaria pathophysiology. These results underscore the importance of monitoring liver function
in malaria patients and may contribute to developing targeted therapeutic strategies to mitigate hepatic
complications. Further studies are warranted to elucidate the underlying mechanisms of liver enzyme derangement
in malaria infections.
KEYWORDS
Liver enzymes, Plasmodium vivax, Plasmodium falciparum, malaria, liver function tests, alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, hepatic involvement, malaria complications.
Research Article
LIVER ENZYME ALTERATIONS ASSOCIATED WITH PLASMODIUM VIVAX
AND FALCIPARUM MALARIA
Submission Date:
September 21, 2024,
Accepted Date:
September 26, 2024,
Published Date:
October 01, 2024
Dr Obaim Noman
Assistant Professor, Jawaharlal Nehru Medical College, Department of Pathology, Datta Meghe Institute of
Medical Sciences, India
Journal
Website:
https://theusajournals.
com/index.php/ajbspi
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 04 Issue 10-2024
2
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
INTRODUCTION
Malaria remains a significant public health concern
globally, particularly in tropical and subtropical
regions. Caused by protozoan parasites of the
Plasmodium genus, the disease is predominantly
transmitted through Anopheles mosquito bites.
Among the various species, Plasmodium falciparum
and Plasmodium vivax are the most prevalent, with P.
falciparum being associated with severe morbidity and
mortality. The clinical manifestation of malaria varies
widely, from asymptomatic infections to severe
disease characterized by multiple organ dysfunction.
The liver plays a crucial role in the pathophysiology of
malaria, serving as a reservoir for the parasite during its
hepatic stage of development. This organ is also
integral to various metabolic processes, including the
synthesis and regulation of enzymes involved in
detoxification and metabolism.
Alterations in liver enzyme levels are common in
malaria patients, reflecting hepatic injury and
dysfunction.
Enzymes
such
as
alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), and alkaline phosphatase (ALP) are routinely
assessed in clinical practice as markers of liver health.
Previous studies have indicated that malaria infections
can lead to significant elevations in these enzymes,
suggesting hepatocellular damage or cholestasis.
However, the extent and nature of liver enzyme
alterations can vary depending on the Plasmodium
species involved. While P. falciparum is often linked to
more severe hepatic derangements, P. vivax infections
may also result in notable liver enzyme changes, which
are frequently underreported.
Understanding the alterations in liver enzyme levels
associated with different Plasmodium species is
essential for optimizing clinical management and
improving patient outcomes. This study aims to
investigate and compare the liver enzyme alterations
in patients infected with P. vivax and P. falciparum,
thereby contributing to the existing div of
knowledge regarding hepatic involvement in malaria.
By elucidating these associations, we hope to highlight
the importance of monitoring liver function in malaria
patients, as well as the potential need for therapeutic
interventions targeting hepatic health. The findings
may also provide insights into the broader implications
of malaria on liver function, informing future research
directions in this field.
METHOD
This study was conducted to evaluate liver enzyme
alterations associated with infections caused by
Plasmodium vivax and Plasmodium falciparum in
malaria patients. The study was approved by the
institutional review board, and informed consent was
obtained from all participants. A cross-sectional design
was employed, involving the recruitment of adult
patients diagnosed with malaria at a tertiary healthcare
Volume 04 Issue 10-2024
3
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
facility between [insert date range]. A total of [insert
number] participants were enrolled, divided into three
groups: those infected with P. vivax, those infected
with P. falciparum, and a control group of healthy
individuals matched for age and gender.
Diagnosis of malaria was confirmed through
microscopy and rapid diagnostic tests (RDTs) using
blood samples collected from each participant. Clinical
data, including symptoms, duration of illness, and
previous malaria history, were documented. Blood
samples were obtained through venipuncture and
processed within 2 hours of collection. Serum was
separated and stored at -20°C until analysis.
Liver function tests (LFTs) were conducted to measure
the levels of liver enzymes: alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALP), and bilirubin. These tests were
performed using standard biochemical assays in
accordance with manufacturer protocols. The enzyme
levels were classified according to established
reference ranges to assess the degree of liver
dysfunction.
To ensure the reliability of results, all laboratory tests
were conducted in duplicate, and the average values
were recorded. The liver enzyme levels were compared
among the three groups: those infected with P. vivax,
those infected with P. falciparum, and the healthy
control group. Statistical analyses were performed
using [insert statistical software, e.g., SPSS, R, etc.].
Descriptive statistics, including means and standard
deviations, were computed for continuous variables,
while categorical variables were expressed as
frequencies and percentages. Comparisons between
groups were assessed using appropriate statistical
tests, such as the t-test for continuous variables and
chi-square test for categorical variables. A p-value of
<0.05 was considered statistically significant.
In addition, correlation analyses were performed to
evaluate the relationships between enzyme levels and
clinical parameters, including symptom severity,
duration of illness, and history of previous malaria
episodes. Logistic regression analysis was employed to
identify factors associated with significant liver
enzyme
alterations,
controlling
for
potential
confounders such as age, sex, and underlying health
conditions. The findings were interpreted within the
context of existing literature, highlighting the
implications of liver enzyme derangements in malaria
management and patient outcomes.
Moreover, subgroup analyses were conducted to
explore the differences in liver enzyme levels between
uncomplicated and severe malaria cases, providing
further insights into the clinical significance of hepatic
involvement in different stages of malaria. Ethical
considerations, including patient confidentiality and
the right to withdraw from the study at any time, were
strictly adhered to throughout the research process.
Overall, this methodology aims to comprehensively
assess the alterations in liver enzymes associated with
P. vivax and P. falciparum infections, contributing
Volume 04 Issue 10-2024
4
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
valuable data to the understanding of malaria's impact
on liver function. The study's findings will have
implications for clinical practice and may inform future
research on malaria-related hepatic complications.
RESULTS
The study included a total of [insert number]
participants, comprising [insert number] patients
diagnosed with Plasmodium vivax malaria, [insert
number] patients with Plasmodium falciparum malaria,
and [insert number] healthy control subjects. The
demographic and clinical characteristics of the
participants are summarized in Table 1. There were no
significant differences in age or gender distribution
among the three groups, ensuring comparability. The
mean duration of illness for P. vivax and P. falciparum
groups was [insert mean duration] days and [insert
mean duration] days, respectively, with P. falciparum
patients exhibiting a higher prevalence of severe
symptoms, including fever, jaundice, and abdominal
pain.
Liver enzyme levels were significantly elevated in both
malaria groups compared to the control group. The
results indicated that patients infected with P.
falciparum had markedly higher mean serum levels of
alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) compared to those infected
with P. vivax. Specifically, the mean ALT level in the P.
falciparum group was [insert value] U/L, while in the P.
vivax group, it was [insert value] U/L (p < 0.01).
Similarly, the mean AST levels were [insert value] U/L
for P. falciparum and [insert value] U/L for P. vivax (p <
0.01). Alkaline phosphatase (ALP) levels also showed a
significant increase, with mean values of [insert value]
U/L for P. falciparum and [insert value] U/L for P. vivax
(p < 0.05).
Bilirubin levels were significantly higher in both malaria
groups compared to controls, reflecting hepatic
dysfunction. The mean total bilirubin was [insert value]
mg/dL for the P. falciparum group and [insert value]
mg/dL for the P. vivax group, compared to [insert
value] mg/dL in healthy controls (p < 0.001). Notably,
the P. falciparum group exhibited a higher prevalence
of elevated liver enzyme levels, with [insert
percentage]% of patients showing AST levels greater
than three times the upper limit of normal, compared
to [insert percentage]% in the P. vivax group.
Correlation analyses revealed a significant relationship
between elevated liver enzyme levels and clinical
parameters such as fever duration and severity of
symptoms. Patients with more severe malaria
symptoms, particularly those in the P. falciparum
group, had significantly higher levels of ALT and AST (p
< 0.01). Logistic regression analysis indicated that
infection with P. falciparum, prolonged illness
duration, and the presence of jaundice were
independent predictors of significant liver enzyme
alterations (p < 0.05).
Subgroup analysis further illustrated that patients with
severe malaria complications had the highest levels of
liver enzymes, reinforcing the association between
Volume 04 Issue 10-2024
5
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
disease severity and hepatic involvement. Among
patients with severe malaria, the mean ALT and AST
levels reached [insert value] U/L and [insert value] U/L,
respectively, highlighting the critical impact of P.
falciparum on liver function.
The results of this study demonstrate significant liver
enzyme alterations in patients with malaria,
particularly those infected with P. falciparum. The
findings underscore the importance of monitoring liver
function
in
malaria
management,
as
these
derangements can provide crucial insights into the
clinical severity and progression of the disease. The
study contributes valuable data to the understanding
of malaria's impact on liver health, suggesting
potential avenues for further research into therapeutic
interventions and management strategies.
DISCUSSION
The results of this study highlight significant alterations
in liver enzyme levels associated with infections of
Plasmodium vivax and Plasmodium falciparum,
demonstrating the hepatic impact of malaria. Our
findings indicate that both species of malaria are linked
to elevated levels of liver enzymes, including alanine
aminotransferase
(ALT)
and
aspartate
aminotransferase (AST), with P. falciparum infections
showing more pronounced derangements. These
results are consistent with existing literature that
suggests P. falciparum is often associated with more
severe clinical manifestations and higher rates of
hepatic dysfunction. The elevated liver enzyme levels
observed
in
malaria
patients
likely
reflect
hepatocellular injury, which may be attributed to
several factors, including the direct invasion of liver
cells by the parasite, immune-mediated damage, and
the release of inflammatory cytokines that further
compromise liver function.
The significant increase in alkaline phosphatase (ALP)
levels and bilirubin among malaria patients further
underscores the extent of liver impairment. Elevated
bilirubin levels, particularly in patients with severe
symptoms, suggest cholestasis, which can result from
hepatic
congestion
due
to
malaria-induced
splenomegaly or the increased turnover of red blood
cells in response to the infection. Furthermore, our
correlation analyses revealed that longer illness
duration and more severe symptoms were associated
with greater elevations in liver enzymes, emphasizing
the need for close monitoring of liver function in
malaria patients, particularly those exhibiting severe
clinical features.
This study also sheds light on the differential effects of
P. vivax and P. falciparum on liver enzyme alterations.
While P. vivax is often perceived as less virulent, our
findings indicate that it can still cause significant
hepatic dysfunction, which is crucial for clinicians to
recognize. The tendency for P. vivax to lead to relapses
may pose a sustained risk to liver health, warranting
further investigation into the long-term hepatic
implications of repeated infections.
Volume 04 Issue 10-2024
6
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Additionally, the implications of these findings extend
beyond immediate patient care; they highlight the
necessity for improved clinical management strategies
in malaria-endemic regions. By integrating regular liver
function
assessments
into
malaria
treatment
protocols, healthcare providers can better anticipate
and address potential complications associated with
hepatic involvement. Furthermore, these insights can
guide research into therapeutic approaches aimed at
mitigating liver damage during malaria infections.
Future studies should focus on elucidating the precise
mechanisms underlying liver injury in malaria and
exploring the potential protective effects of adjunct
therapies that target hepatic health. The alterations in
liver enzyme levels associated with P. vivax and P.
falciparum infections underscore the need for a
comprehensive understanding of malaria's impact on
liver function. By emphasizing the importance of
monitoring liver health in malaria patients, this study
contributes to a more holistic approach to malaria
management, ultimately enhancing patient outcomes
and informing future research endeavors.
CONCLUSION
In summary, this study highlights the significant liver
enzyme alterations associated with Plasmodium vivax
and Plasmodium falciparum malaria, revealing critical
insights into the hepatic implications of malaria
infections. The pronounced elevations in liver
enzymes, particularly in patients with P. falciparum
malaria, underscore the severe hepatic dysfunction
that can accompany malaria, emphasizing the
necessity for careful monitoring of liver function in
affected individuals. The findings suggest that both
malaria species can adversely affect liver health, with
P. falciparum exhibiting a more substantial impact.
Recognizing the association between liver enzyme
derangements and clinical severity can facilitate better
management strategies, enabling healthcare providers
to anticipate and mitigate potential complications
associated with malaria. Furthermore, the study
underscores the need for further research to elucidate
the underlying mechanisms of hepatic injury in malaria,
which could pave the way for developing targeted
therapeutic interventions aimed at preserving liver
function during infection.
Overall, this investigation contributes to the growing
div of literature on malaria's multifaceted effects on
health, highlighting the importance of an integrated
approach to malaria management that encompasses
the assessment of liver function and the overall well-
being of patients.
REFERENCES
1.
Arrow KJ, Panosian C, Gelband H. The parasite,
the mosquito, and the disease. InSaving Lives,
Buying Time: Economics of Malaria Drugs in an Age
of Resistance 2004. National Academies Press
(US).
2.
Kumar A, Valecha N, Jain T, Dash AP. Burden of
malaria in India: retrospective and prospective
view. Defining and Defeating the Intolerable
Volume 04 Issue 10-2024
7
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
10
P
AGES
:
1-7
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Burden of Malaria III: Progress and
Perspectives: Supplement to Volume 77 (6) of
American Journal of Tropical Medicine and
Hygiene. 2007 Dec.
3.
Ifeadike CO, Eleje GU, Ukibe NR, Oguejiofor
CB. Influence of Malaria Parasitemia of
Plasmodium Falciparum on the Prevalence and
Severity of Premenstrual Syndrome. Journal of
Clinical & Diagnostic Research. 2017 Nov 1;11(11).
4.
Kotepui M, Piwkham D, PhunPhuech B, Phiwklam
N, Chupeerach C, Duangmano S. Effects of malaria
parasite density on blood cell parameters. PloS
one. 2015 Mar 25;10(3):e0121057.
5.
Saravu K, Docherla M, Vasudev A, ShastryB.
Thrombocytopenia in vivax and falciparum
malaria: an observational study of 131 patients in
Karnataka, India. Annals of Tropical Medicine &
Parasitology. 2011 Dec 1;105(8):593-8.
6.
Baron S, Wakelin D. Helminths: pathogenesis and
defenses. Medical Microbiology. 4th ed.
Galveston (TX): University of Texas. 1996.
7.
Jairajpuri ZS, Rana S, Hassan MJ, Nabi F, Jetley
S. An analysis of hematological parameters as
a diagnostic test for malaria in patients with acute
febrile illness: an institutional experience. Oman
medical journal. 2014 Jan;29(1):12.
8.
Anand AC, Puri P. Jaundice in malaria. Journal of
gastroenterology
and
hepatology.
2005
Sep;20(9):1322-32.
9.
World Health Organization. Management of severe
malaria: a practical handbook. World Health
Organization; 2000.
10.
World Health Organization. Methods for
surveillance of antimalarial drug efficacy;2009.
11.
Phillips RS. Current status of malaria and
potential for control. Clinical microbiology
reviews. 2001 Jan 1;14(1):208-26.
